Previous 10 | Next 10 |
2023-03-23 08:08:44 ET Summary Halvorsen's 13F portfolio value decreased from $21.66B to ~$19.98B this quarter. The number of positions decreased from 88 to 53. Viking Global increased Amazon and UnitedHealth while decreasing General Electric, Meta Platforms, and Boston Scientific...
2023-03-21 07:43:24 ET A top FDA official said Monday that the agency needs to consider accelerated approval, a regulatory avenue commonly used to expedite the market entry of cancer drugs, for gene therapies. Dr. Peter Marks, who heads the FDA's biologics unit, said that the agency...
2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...
BioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Achondroplasia PR Newswire New Analyses from Phase 2 and Phase 3 Extension Stud...
2023-03-08 10:51:52 ET Summary Roche has logged a few clinical successes lately, but hasn't scored the sort of big wins that change investment theses or drive lasting changes in sentiment. Fourth quarter pharmaceutical sales were fine, and Roche has a strong roster of $1B-plus/yea...
2023-03-07 17:58:11 ET BioMarin Pharmaceutical ( NASDAQ: BMRN ) on Tuesday said the U.S. Food and Drug Administration (FDA) had cleared expanding the use of its Voxzogo treatment in children with short stature under the age of five. The FDA accepted BMRN's supplemental...
FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5 PR Newswire The Supplemental New Drug Application is Based on Positive Results from Global Randomized Pha...
2023-03-07 00:26:15 ET The US FDA has told BioMarin Pharmaceutical ( NASDAQ: BMRN ) that it is extending the action date on the company's Biologics License Application for Roctavian (valoctocogene roxaparvovec) to June 30. The FDA said that a three-year data analysis provi...
BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A PR Newswire FDA Extends PDUFA Target Action Date to June 30, 2023 SAN RAFAEL, Calif. , March 6, 2023 /PRNewswire/...
2023-03-06 08:17:23 ET Aclaris Therapeutics ( ACRS ) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa . Esperion Therapeutics ( ESPR ) -27% amid Nexletol data ...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...